Bioaffinity Technologies Inc (BIAF) Stock Price, Quote & News

Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, incl...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 210 698 5334

Website: www.bioaffinitytech.com

Address:

3300 Nacogdoches Road, Suite 216, San Antonio, United States

Logic102 Nov. 14 at 7:24 PM

$BIAF Lung cancer kills more people annually than Breast, Colon and Prostate cancers COMBINED and we have a non-invasive early detection test that can save thousands of lives "the Cologuard of Lung Cancer." CyPath is a loaded Gold Mine.

0 · Reply

LockPopSell Nov. 14 at 4:21 PM

$BIAF does scare me insiders are not accumulating...

1 · Reply

LockPopSell Nov. 14 at 4:18 PM

$BIAF I mean if its not a complete scam lol, it seems legit.. I mean getting footholds in international markets especially China, and already in the VA system is huge.... IDK could be a gem long term

1 · Reply

TheRealRazingCane Nov. 14 at 2:44 PM

$BIAF Zannes is a liar - she's been hyping the "increased popularity" of this test for several quarters now. Leave it to an attorney...

1 · Reply

cubie Nov. 14 at 2:19 PM

$AVXL $SBFM $AVXL $SBFM $BIAF $SLNH And useless pumptard baggie #7 @Animalhouse123 sealed the deal, its official avxl gonna drop Some these fools are so bad, u follow them just to do the opposite! Cubie teaches 🤭😆😁🫡

0 · Reply

Hotresearchsgoldenage Nov. 14 at 1:32 PM

$BIAF I’m Not saying investors are wrong here but could be early ? It’s definitely a buy but when ? Now ? Wait ? 🤷🏼‍♂️

0 · Reply

Kumbaya171 Nov. 14 at 1:10 PM

$BIAF finally some recogntion for a great small cap company!!

0 · Reply

Hotresearchsgoldenage Nov. 14 at 1:02 PM

$BIAF how ! Geez

1 · Reply

SquidGainz Nov. 13 at 11:35 PM

$VOR $BIAF $ECDA $ATHA 0

0 · Reply

Logic102 Nov. 13 at 9:05 PM

$BIAF Bought more shares near the close today.

1 · Reply

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 8:00 AM EST - 9 days ago

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

Oct 28, 2025, 8:00 AM EDT - 17 days ago

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

Oct 20, 2025, 8:00 AM EDT - 25 days ago

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

Oct 16, 2025, 8:00 AM EDT - 4 weeks ago

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

Oct 15, 2025, 8:00 AM EDT - 4 weeks ago

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

Oct 9, 2025, 2:00 PM EDT - 5 weeks ago

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 9, 2025, 1:00 PM EDT - 5 weeks ago

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 4:15 PM EDT - 5 weeks ago

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 3:45 PM EDT - 5 weeks ago

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 7, 2025, 8:00 AM EDT - 5 weeks ago

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

Sep 30, 2025, 12:44 PM EDT - 6 weeks ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

Sep 30, 2025, 12:15 PM EDT - 6 weeks ago

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

Sep 29, 2025, 5:59 PM EDT - 6 weeks ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

Sep 29, 2025, 3:51 PM EDT - 6 weeks ago

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

Sep 26, 2025, 8:00 AM EDT - 7 weeks ago

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

Sep 17, 2025, 8:15 AM EDT - 2 months ago

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Sep 9, 2025, 8:00 AM EDT - 2 months ago

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

Aug 18, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Appoints New Members to Board of Directors

Aug 14, 2025, 4:15 PM EDT - 3 months ago

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 14, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Reports Second Quarter 2025 Results

Aug 13, 2025, 9:25 AM EDT - 3 months ago

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 13, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Jul 29, 2025, 8:00 AM EDT - 3 months ago

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Jul 22, 2025, 9:00 AM EDT - 4 months ago

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

Jul 15, 2025, 9:00 AM EDT - 4 months ago

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

Jun 26, 2025, 9:00 AM EDT - 5 months ago

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

Jun 24, 2025, 9:00 AM EDT - 5 months ago

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

Jun 11, 2025, 9:00 AM EDT - 5 months ago

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

May 28, 2025, 9:00 AM EDT - 6 months ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 20, 2025, 9:00 AM EDT - 6 months ago

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 15, 2025, 8:30 AM EDT - 6 months ago

bioAffinity Technologies Reports First Quarter 2025 Results

May 8, 2025, 9:00 AM EDT - 6 months ago

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 7, 2025, 1:15 PM EDT - 6 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

May 7, 2025, 1:00 PM EDT - 6 months ago

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 6, 2025, 10:30 AM EDT - 6 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

May 6, 2025, 9:25 AM EDT - 6 months ago

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

Apr 17, 2025, 9:15 AM EDT - 7 months ago

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Mar 31, 2025, 9:28 AM EDT - 8 months ago

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Mar 26, 2025, 9:00 AM EDT - 8 months ago

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 19, 2025, 9:00 AM EDT - 8 months ago

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Mar 13, 2025, 9:00 AM EDT - 8 months ago

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Mar 6, 2025, 8:00 AM EST - 9 months ago

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Feb 26, 2025, 12:10 PM EST - 9 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 11:30 AM EST - 9 months ago

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 11:05 AM EST - 9 months ago

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 9:58 AM EST - 9 months ago

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Jan 22, 2025, 8:00 AM EST - 10 months ago

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Jan 13, 2025, 8:00 AM EST - 10 months ago

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Jan 10, 2025, 9:00 AM EST - 11 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ENLV

Logic102 Nov. 14 at 7:24 PM

0 · Reply

LockPopSell Nov. 14 at 4:21 PM

$BIAF does scare me insiders are not accumulating...

1 · Reply

LockPopSell Nov. 14 at 4:18 PM

$BIAF I mean if its not a complete scam lol, it seems legit.. I mean getting footholds in international markets especially China, and already in the VA system is huge.... IDK could be a gem long term

1 · Reply

TheRealRazingCane Nov. 14 at 2:44 PM

$BIAF Zannes is a liar - she's been hyping the "increased popularity" of this test for several quarters now. Leave it to an attorney...

1 · Reply

cubie Nov. 14 at 2:19 PM

0 · Reply

Hotresearchsgoldenage Nov. 14 at 1:32 PM

$BIAF I’m Not saying investors are wrong here but could be early ? It’s definitely a buy but when ? Now ? Wait ? 🤷🏼‍♂️

0 · Reply

Kumbaya171 Nov. 14 at 1:10 PM

$BIAF finally some recogntion for a great small cap company!!

0 · Reply

Hotresearchsgoldenage Nov. 14 at 1:02 PM

$BIAF how ! Geez

1 · Reply

SquidGainz Nov. 13 at 11:35 PM

$VOR $BIAF $ECDA $ATHA 0

0 · Reply

Logic102 Nov. 13 at 9:05 PM

$BIAF Bought more shares near the close today.

1 · Reply

MakeM0ney_444 Nov. 13 at 8:59 PM

$BIAF are they still going at it alone? When a buyout or partnership?

0 · Reply

Lovemypicks Nov. 13 at 8:25 PM

$BIAF it’s at 6.5 cents from pre split levels - dilution has been minimal somebody up there hates this stock or they want the whole thing at a ridiculous discount

0 · Reply

LockPopSell Nov. 13 at 5:43 PM

$BIAF is it scary that I own more shares than the CEO.. yes yes it is

2 · Reply

LockPopSell Nov. 13 at 5:40 PM

$BIAF you know whats not accelerating month over month fucking Bioaffinity, your stock price

0 · Reply

Stonecrest Nov. 13 at 3:53 PM

$BIAF What the hell just happened. Why did it recover that fast?

0 · Reply

Extramoneypls Nov. 13 at 2:18 PM

$BIAF I have been emailing back and forth with IR about earnings release. They stated the intend to file today (did not specify before or after market) but that they have until Friday to file, so it might be tomorrow.

4 · Reply

AlSookTraders Nov. 13 at 11:16 AM

$BIAF any day now, discord team is locked and loaded.

1 · Reply

Hotresearchsgoldenage Nov. 13 at 11:11 AM

$BIAF the Payent for China is approved and expected to be granted this month .

0 · Reply

Millaros Nov. 13 at 11:05 AM

$BIAF I thought earnings was due here but can't find anything?

1 · Reply

Hotresearchsgoldenage Nov. 12 at 9:35 PM

$BIAF she was a bear on $APLD when it was 4$ ! 😜🤣🤣🤣🤣 Shut the front door !!

0 · Reply

Hotresearchsgoldenage Nov. 12 at 9:33 PM

$BIAF tons of new doctors on board ! Tons ! Bullish af !

1 · Reply

Lovemypicks Nov. 12 at 8:37 PM

$BIAF it’s a buyout candidate here 12-15 easy - how you doin?

0 · Reply

Market Cap	7.81M
Revenue (ttm)	9.36M
Net Income (ttm)	-9.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-96.58%
Debt to Equity Ratio	-0.04

Volume	120,768
Avg Vol	3,619,345
Day's Range	N/A - N/A
Shares Out	3.63M
Stochastic %K	0%
Beta	2.31
Analysts	Hold
Price Target	$6.00